U.S. markets open in 29 minutes
  • S&P Futures

    4,193.75
    -28.50 (-0.67%)
     
  • Dow Futures

    33,530.00
    -275.00 (-0.81%)
     
  • Nasdaq Futures

    14,093.00
    -72.50 (-0.51%)
     
  • Russell 2000 Futures

    2,256.60
    -27.90 (-1.22%)
     
  • Crude Oil

    70.28
    -0.76 (-1.07%)
     
  • Gold

    1,777.20
    +2.40 (+0.14%)
     
  • Silver

    26.05
    +0.19 (+0.73%)
     
  • EUR/USD

    1.1889
    -0.0021 (-0.18%)
     
  • 10-Yr Bond

    1.5120
    +0.0010 (+0.07%)
     
  • Vix

    20.36
    +2.21 (+12.18%)
     
  • GBP/USD

    1.3850
    -0.0074 (-0.53%)
     
  • USD/JPY

    110.2600
    +0.0290 (+0.03%)
     
  • BTC-USD

    37,420.50
    -1,345.19 (-3.47%)
     
  • CMC Crypto 200

    925.38
    -44.49 (-4.59%)
     
  • FTSE 100

    7,044.86
    -108.57 (-1.52%)
     
  • Nikkei 225

    28,964.08
    -54.25 (-0.19%)
     

MESO Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Mesoblast Limited Investors of Class Action and Lead Plaintiff Deadline: December 7, 2020

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

New York, New York--(Newsfile Corp. - December 2, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Mesoblast Limited ("Mesoblast" or "the Company") (NASDAQ: MESO) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Mesoblast securities between April 16, 2019 and October 1, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/meso.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements that: (1) comparative analyses between Mesoblast's Phase 3 trial and three historical studies did not support the effectiveness of remestemcel-L for steroid refractory acute graft versus host disease ("aGVHD") due to design differences between the four studies; (2) as a result, the United States Food and Drug Administration was reasonably likely to require further clinical studies; (3) as a result, the commercialization of remestemcel-L in the U.S. was likely to be delayed; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/meso or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Mesoblast you have until December 7, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/68966